164 related articles for article (PubMed ID: 22480734)
21. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
[TBL] [Abstract][Full Text] [Related]
22. Agonist binding fraction of dopamine D2/3 receptors in rat brain: a quantitative autoradiographic study.
Minuzzi L; Cumming P
Neurochem Int; 2010; 56(6-7):747-52. PubMed ID: 20117160
[TBL] [Abstract][Full Text] [Related]
23. In vitro binding of [(11)C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography.
Noguchi J; Zhang MR; Yanamoto K; Nakao R; Suzuki K
Nucl Med Biol; 2008 Jan; 35(1):19-27. PubMed ID: 18158939
[TBL] [Abstract][Full Text] [Related]
24. Autoradiographic analysis of dopamine receptor-stimulated [(35)S]GTPgammaS binding in rat striatum.
He L; Di Monte DA; Langston JW; Quik M
Brain Res; 2000 Dec; 885(1):133-6. PubMed ID: 11121540
[TBL] [Abstract][Full Text] [Related]
25. Decrease of D2 receptor binding but increase in D2-stimulated G-protein activation, dopamine transporter binding and behavioural sensitization in brains of mice treated with a chronic escalating dose 'binge' cocaine administration paradigm.
Bailey A; Metaxas A; Yoo JH; McGee T; Kitchen I
Eur J Neurosci; 2008 Aug; 28(4):759-70. PubMed ID: 18671743
[TBL] [Abstract][Full Text] [Related]
26. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease.
Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ
Brain; 2008 May; 131(Pt 5):1294-302. PubMed ID: 18362097
[TBL] [Abstract][Full Text] [Related]
27. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain.
Talbot JN; Happe HK; Murrin LC
J Pharmacol Exp Ther; 2005 Aug; 314(2):596-602. PubMed ID: 15860573
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation.
Quirk K; Roberts DJ; Strange PG
Br J Pharmacol; 2007 May; 151(1):144-52. PubMed ID: 17351658
[TBL] [Abstract][Full Text] [Related]
29. Low density of dopamine D4 receptors in Parkinson's, schizophrenia, and control brain striata.
Seeman P; Guan HC; Van Tol HH; Niznik HB
Synapse; 1993 Aug; 14(4):247-53. PubMed ID: 8248849
[TBL] [Abstract][Full Text] [Related]
30. Cocaine alters mu but not delta or kappa opioid receptor-stimulated in situ [35S]GTPgammaS binding in rat brain.
Schroeder JA; Niculescu M; Unterwald EM
Synapse; 2003 Jan; 47(1):26-32. PubMed ID: 12422370
[TBL] [Abstract][Full Text] [Related]
31. Apparent dopamine D1 and D2 receptors in the weaver mutant mouse: receptor binding and coupling to adenylyl cyclase.
Dewar KM; Paquet M; Sequeira A
J Neural Transm (Vienna); 1999; 106(5-6):487-97. PubMed ID: 10443552
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.
Vanhauwe JF; Fraeyman N; Francken BJ; Luyten WH; Leysen JE
J Pharmacol Exp Ther; 1999 Aug; 290(2):908-16. PubMed ID: 10411608
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization of dopamine-stimulated [35S]-guanosine 5'(gamma-thiotriphosphate) ([35S]GTPgammaS) binding in rat striatal membranes.
Rinken A; Finnman UB; Fuxe K
Biochem Pharmacol; 1999 Jan; 57(2):155-62. PubMed ID: 9890563
[TBL] [Abstract][Full Text] [Related]
34. Effect of denervation of the locus coeruleus projections by DSP-4 treatment on [3H]-raclopride binding to dopamine D(2) receptors and D(2) receptor-G protein interaction in the rat striatum.
Harro J; Terasmaa A; Eller M; Rinken A
Brain Res; 2003 Jun; 976(2):209-16. PubMed ID: 12763255
[TBL] [Abstract][Full Text] [Related]
35. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
[TBL] [Abstract][Full Text] [Related]
36. Characterization of dopamine D
Egusquiza I; Munarriz-Cuezva E; Segarra R; González-Maeso J; Callado LF; Meana JJ; Diez-Alarcia R
Pharmacol Rep; 2021 Aug; 73(4):1136-1146. PubMed ID: 34196951
[TBL] [Abstract][Full Text] [Related]
37. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism.
Volkow ND; Logan J; Fowler JS; Wang GJ; Gur RC; Wong C; Felder C; Gatley SJ; Ding YS; Hitzemann R; Pappas N
Am J Psychiatry; 2000 Jan; 157(1):75-80. PubMed ID: 10618016
[TBL] [Abstract][Full Text] [Related]
38. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease.
Kaasinen V; Någren K; Hietala J; Oikonen V; Vilkman H; Farde L; Halldin C; Rinne JO
Neurology; 2000 Apr; 54(7):1482-7. PubMed ID: 10751262
[TBL] [Abstract][Full Text] [Related]
39. Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.
Sun J; Cairns NJ; Perlmutter JS; Mach RH; Xu J
Neuroscience; 2013 Sep; 248():112-26. PubMed ID: 23732230
[TBL] [Abstract][Full Text] [Related]
40. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
Selley DE; Rorrer WK; Breivogel CS; Zimmer AM; Zimmer A; Martin BR; Sim-Selley LJ
J Neurochem; 2001 May; 77(4):1048-57. PubMed ID: 11359870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
